Sign Up to Receive Your Personalised Learning Resources

Start Learning
Is there an alternative to intensive chemotherapy for patients with acute myeloid leukemia? Key insights from ASH 2024
Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024
CE/CME ACCREDITED
#EHA2025: Are menin inhibitors the next standard of care for high-risk AML?
Positive phase III VERIFY study results for rusfertide in polycythemia vera
Greatest Hits of 2024
#EHA2025: AnitoCell shows promise in RRMM with 97% ORR in iMMagine-1
Dr Elena Crisà on how precision medicine is revolutionalizing haematology: touchHAEMATOLOGY Future Leader 2025
Looking to the future in the treatment of steroid-refractory chronic GvHD
CE/CME ACCREDITED
#ASH24: Must-know updates in multiple myeloma
Empowering young haematologists: Insights from the EBMT Trainee Committee co-chairs
Is there an alternative to intensive chemotherapy for patients with acute myeloid leukemia? Key insights from ASH 2024
Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024
CE/CME ACCREDITED
#EHA2025: Are menin inhibitors the next standard of care for high-risk AML?
Positive phase III VERIFY study results for rusfertide in polycythemia vera
Greatest Hits of 2024
#EHA2025: AnitoCell shows promise in RRMM with 97% ORR in iMMagine-1
Dr Elena Crisà on how precision medicine is revolutionalizing haematology: touchHAEMATOLOGY Future Leader 2025
Looking to the future in the treatment of steroid-refractory chronic GvHD
CE/CME ACCREDITED
#ASH24: Must-know updates in multiple myeloma
Empowering young haematologists: Insights from the EBMT Trainee Committee co-chairs
Is there an alternative to intensive chemotherapy for patients with acute myeloid leukemia? Key insights from ASH 2024
Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024
CE/CME ACCREDITED
#EHA2025: Are menin inhibitors the next standard of care for high-risk AML?
Positive phase III VERIFY study results for rusfertide in polycythemia vera
Sign up to view Favourites, Keep Notes and Track CME Credits
Favourites
What’s new in primary ITP? Key updates from ASH 2024
View
#ASH24: The countdown is on!
View
Coming soon! touchHAEMATOLOGY Future Leaders 2025
View
#EHA25: INCA33989 shows promise as disease-modifying therapy for essential thrombocythemia
View
Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024
View
EHA 2025: The countdown is on!
View
#ASCO25: Dr Miguel-Angel Perales unveils the CAR T Vision Coalition
View
DREPAGREFFE: Comparing stem cell transplantation and standard-of-care in paediatric sickle cell anaemia
View
#EHA2025: Are menin inhibitors the next standard of care for high-risk AML?
View
Navigating the treatment of RRMM with BCMA-directed therapies: Updates from COMy, ASCO and EHA 2025
View
Journal articles and more to your inbox
Get the latest clinical insights from touchHAEMATOLOGY
Sign me up!